Welcome to our dedicated page for Obsidian Therapeutics SEC filings (Ticker: OBX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Obsidian Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Obsidian Therapeutics's regulatory disclosures and financial reporting.
Obsidian Therapeutics, Inc. director Heidi Hagen received a stock option grant covering 37,653 shares of common stock on 2026-08-03. The option has an exercise price of $12.00 per share and expires on 2036-08-02. The shares vest upon the earlier of the one-year anniversary of the grant date or the company’s next annual stockholders’ meeting, subject to her continued service.
Obsidian Therapeutics, Inc. director Maria Fardis received a compensatory stock option grant for 37,653 shares of common stock on August 3, 2026. The option has an exercise price of $12.00 per share and expires on August 2, 2036. The shares underlying this option vest and become exercisable upon the earlier of the one-year anniversary of the grant date or the issuer's annual meeting of stockholders following the grant date, subject to her continued service.
Obsidian Therapeutics, Inc. identified Peter Barrett as a director and reporting person in an initial beneficial ownership report. The filing does not list any stock or option transactions and includes an exhibit described as a Power of Attorney.
Obsidian Therapeutics, Inc. director Maria Fardis reported her initial holdings of stock options. She holds four direct option positions, each with an exercise price of $0.78 per share and expirations in 2031, 2032, 2033 and 2034, covering underlying common stock. Options expiring in 2031, 2032 and 2033 cover 355,000, 290,000 and 80,000 shares and are fully vested and exercisable. The option expiring in 2034 covers 497,500 shares that vest in sixteen equal quarterly installments following June 25, 2024, conditioned on her continued service.
Obsidian Therapeutics, Inc. officer Julie B. Feder, Chief Financial Officer, reported initial beneficial ownership of two stock option awards on common stock. Both options have an exercise price of $0.7800 per share and expire on January 20, 2036.
One option covers 2,732,337 underlying shares, with 25% vesting on January 12, 2027 and the remainder vesting in 12 equal quarterly installments thereafter, subject to continued service. The other option covers 271,604 underlying shares, with 50% vesting on September 30, 2026 and the remainder vesting in eight equal quarterly installments, also conditioned on continued service.
Obsidian Therapeutics director Heidi Hagen reported existing stock option holdings in connection with becoming an insider. The holdings include two options to purchase Obsidian common stock at an exercise price of $0.78 per share. One option covers 180,000 underlying shares, is fully vested and exercisable, and expires on November 30, 2031. The second option covers 337,500 underlying shares, expires on June 24, 2034, and vests in 16 equal quarterly installments beginning after June 25, 2024, contingent on continued service.
Obsidian Therapeutics, Inc. director and Chief Executive Officer Madan Jagasia reported beneficial ownership of several stock options to buy Common Stock of the company. These options carry an exercise price of $0.7800 per share and various vesting schedules and expiration dates.
Holdings include stock options expiring on February 27, 2033 covering, among others, 7,081,478 underlying shares with 25% vested on January 30, 2024 and the remainder vesting in twelve equal quarterly installments, as well as additional grants that are fully vested and exercisable. Another option expiring on June 24, 2034 covers 4,154,000 underlying shares, vesting in forty-eight equal monthly installments following June 25, 2024, subject to continued service.
Obsidian Therapeutics, Inc. director Matthew Norkunas reported his initial equity holdings. He holds stock options to acquire 180,000 shares of common stock at an exercise price of $0.7800 per share expiring May 24, 2033, and additional options over 51,563 shares at the same exercise price expiring June 24, 2034. These options vest in sixteen equal quarterly installments starting June 30, 2023 and June 25, 2024, respectively, subject to his continued service. He also directly holds 30,937 shares of common stock.
Obsidian Therapeutics, Inc. reports the initial equity holdings of Chief Medical Officer Hari Parameswaran. The filing lists several stock options (right to buy) over Common Stock with an exercise price of $0.7800 per share and expirations on February 27, 2033 and June 24, 2034. One option covering 1,770,369 underlying shares began vesting with 25% exercisable on January 17, 2024, with the balance vesting in twelve equal quarterly installments, subject to continued service. Additional options over 48,685 and 97,370 underlying shares are fully vested and exercisable. A further option for 943,500 underlying shares vests in sixteen equal monthly installments following June 25, 2024, also conditioned on continued service. No purchases or sales are reported; this statement records existing option positions.
Obsidian Therapeutics, Inc. director Robert W. Ross reported his initial beneficial ownership, consisting solely of stock options over common stock. The reported positions include options exercisable at $0.71 per share for 180,000 underlying shares, fully vested and exercisable, and additional options exercisable at $0.78 per share for 175,000 and 162,500 underlying shares. The latter grant vests in sixteen equal quarterly installments following June 25, 2024, subject to his continued service.